Clinical trials: Telomere
Critical Limb Ischemia
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many diseases related to aging, including critical limb ischemia (CLI).
- Trial name
- NCT04110964
- Testing
- AAV-hTERT
- Where
- Colombia
- Volunteers
- 5 people
- Sponsor
- Libella Gene Therapeutics
Telomere Biology Disorders With Bone Marrow Failure
Rollover Study From EXG-US-01
This is a long-term rollover follow-up study for Phase I/II study (Protocol EXG-US-01).
- Trial name
- NCT05868499
- Testing
- EXG34217
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Elixirgen Therapeutics, Inc.
Aging
Evaluation of Safety and Tolerability of Libella Gene Therapy for the Treatment of Aging: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in humans has the potential to treat many of the age related diseases, including Aging itself.
- Trial name
- NCT04133649
- Testing
- AAV-hTERT
- Where
- Colombia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Libella Gene Therapeutics
Healthy
Effect of TA-65MD on Healthy Volunteers
TA-65 MD® is pure, natural, plant-based compound that can help maintain or rebuild telomeres. A telomere is a region of repetitive DNA at the end of a chromosome, which protects the end of the chromosome from deterioration.
- Trial name
- TA-65MD (NCT02766790)
- Testing
- TA-65MD
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Telomerase Activation Sciences, Inc
Prostate Cancer
Telomere Associated Variables (TAVs) in Prostate Cancer
This research project results from the interest in continuing the collaboration with the previous LL-HURS-ONC001 clinical validation study, which gives cause to the present study.
- Trial name
- NCT04124900
- Where
- 10 sites in United States, Spain
- Volunteers
- 509 people
- Sponsor
- Life Length SL
Aging
AC-11 Supplement and Biological Aging
This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age.
- Trial name
- NCT05310123
- Testing
- AC-11
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Alzheimer Disease
Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
- Trial name
- NCT04133454
- Testing
- AAV-hTERT
- Where
- Colombia
- Volunteers
- 5 people
- Sponsor
- Libella Gene Therapeutics
Idiopathic Infertility, Infertility Unexplained
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility
The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained…
- Conditions
- Idiopathic Infertility, Infertility Unexplained, Infertility (IVF Patients), Infertility Assisted Reproductive Technology
- Trial name
- TECMI (NCT07404969)
- Testing
- 1. Aging Hallmarks Biomarker Profiling (Telomere-Based), 2. Integrative Botanical and Nutraceutical Intervention, 3. Natural Conception or Assisted Reproductive Technologies
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- BEYOND GENOMiX SA, AG, Ltd
Telomere Shortening, Bone Marrow Failure
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
This is a Phase I/II, open label, single center study to assess the safety and tolerability of EXG34217 in bone marrow failure patients with telomere biology disorders.
- Trial name
- NCT04211714
- Testing
- EXG34217
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Elixirgen Therapeutics, Inc.